The effect of homozygous deletion of the BBOX1 and Fibin genes on carnitine level and acyl carnitine profile. by Rashidi-Nezhad, A. et al.
Rashidi-Nezhad et al. BMC Medical Genetics 2014, 15:75
http://www.biomedcentral.com/1471-2350/15/75CASE REPORT Open AccessThe effect of homozygous deletion of the BBOX1
and Fibin genes on carnitine level and acyl
carnitine profile
Ali Rashidi-Nezhad1,2,3, Saeed Talebi2, Homeira Saebnouri2, Seyed Mohammad Akrami2* and Alexandre Reymond1*Abstract
Background: Carnitine is a key molecule in energy metabolism that helps transport activated fatty acids into the
mitochondria. Its homeostasis is achieved through oral intake, renal reabsorption and de novo biosynthesis. Unlike
dietary intake and renal reabsorption, the importance of de novo biosynthesis pathway in carnitine homeostasis
remains unclear, due to lack of animal models and description of a single patient defective in this pathway.
Case presentation: We identified by array comparative genomic hybridization a 42 months-old girl homozygote
for a 221 Kb interstitial deletions at 11p14.2, that overlaps the genes encoding Fibin and butyrobetaine-gamma
2-oxoglutarate dioxygenase 1 (BBOX1), an enzyme essential for the biosynthesis of carnitine de novo. She presented
microcephaly, speech delay, growth retardation and minor facial anomalies. The levels of almost all evaluated
metabolites were normal. Her serum level of free carnitine was at the lower limit of the reference range, while her
acylcarnitine to free carnitine ratio was normal.
Conclusions: We present an individual with a completely defective carnitine de novo biosynthesis. This condition
results in mildly decreased free carnitine level, but not in clinical manifestations characteristic of carnitine deficiency
disorders, suggesting that dietary carnitine intake and renal reabsorption are sufficient to carnitine homeostasis. Our
results also demonstrate that haploinsufficiency of BBOX1 and/or Fibin is not associated with Primrose syndrome as
previously suggested.
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Carnitine (L-3-hydroxy-4-N,N,N-trimethylaminobutyrate)
is crucial for energy metabolism. It is a conditional essen-
tial nutrient found in animals, numerous microorganisms
and plants [1-3]. It allows the transport of activated fatty
acids from the cytosol to the mitochondria, where they
are beta-oxidized. Other functions of carnitine include
peroxisome fatty acid oxidation, modulating intracellular
coenzyme A homeostasis and removal of excess acyl
groups from the body via the preferential renal excretion
of acylcarnitines [4-7].* Correspondence: akramism@tums.ac.ir; Alexandre.reymond@unil.ch
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article, unless otherwise stated.In mammals, carnitine homeostasis is achieved and
maintained by a combination of absorption from dietary
sources, de novo biosynthesis and efficient, renal tubular
reabsorption [4,8]. Diet is the primary source of carni-
tine and dietary bioavailability of L-carnitine can vary
considerably because of the broad range of nutritional
choice. Meat, fish and dairy products are main sources
in human, so vegetarians obtain very low amount of car-
nitine from their diet. However, compensatory mecha-
nisms, including renal reabsorption in conjugation with
de novo biosynthesis, are proficient in conserving carni-
tine homeostasis when dietary L-carnitine consumption
is low [4,8,9].
L-carnitine is synthesized from the amino acid precur-
sors lysine and methionine via four enzymatic reactions.
These enzymes are found in all the human cells, with
the exception of butyrobetaine-gamma 2-oxoglutarate
dioxygenase 1(BBOX1) that is only expressed in the liver,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Proband’s anthropometric measurements
Physical characteristics Birth Z-score 42 mths Z-score
Weight 2.4 kg −1.99 9.5 kg −3.58
Height 44 cm −2.76 80 cm −4.85
Head circumference 29 cm −4.12 37.5 cm −8
Body Mass Index (BMI) 12.40 −0.79 15.1 −0.15
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http://www.biomedcentral.com/1471-2350/15/75kidneys and brain [5,10]. In contrast to the diet and renal
reabsorption, the significance of carnitine de novo biosyn-
thesis for energy homeostasis remains unclear [8], as no
animal model and a single patient were described. While
this patient was deficient for trimethyllysine hydroxylase
epsilon (TMLHE), the first enzyme of the carnitine bio-
synthesis pathway [11,12], we report on the first instance
of homozygous deletion of BBOX1, the last enzyme of
that pathway.
Case presentation
The proband girl was born at 38 weeks of gestation to a
23 years old mother after an uneventful pregnancy. Ac-
cording to birth measurements, she suffered from Intra
uterine growth restriction (IUGR) with disproportionate
congenital microcephaly (Table 1). The parents are first-
degree cousins. They have a second healthy child boy
and did not experience any abortion or child death.
Investigation of the family tree identified the spontan-
eous abortion of a first-degree cousin and a girl, 6th
degree proband’s relative, presented hypotonia, mental
retardation and facial dysmorphism. At 42 months, the
proband presented a mild dysmorphic face with short
forehead, high nasal bridge and flat nasal root, down slant
pulpebral fissure, epicanthal folds, mild strabismus, long
eye lashes, retrognathia and large ears relative to her face
(Figure 1A-B). Her anthropometric measurements showed
growth retardation (Table 1). She was hyperactive with a
history of drooling and several attacks of unprovoked
seizures that are now under control without antiepilepticFigure 1 Proband’s facial (A) and ear (B) appearance.drug. Her neurological examination showed a mild gener-
alized hypertonia with mild contracture in knees but her
balance, motor, sensory and reflexes were all in the normal
ranges. The proband, has a history of motor delay and
spasticity in lower limbs, which was improved with phys-
ical therapy. On the contrary her speech delay showed no
improvement upon therapy. The proband social and
cognition axes of development were almost normal. The
auditory brainstem response (ABR) was also normal.
However, the brain magnetic resonance imaging (MRI)
showed severe microcephaly and small frontal lobes with
no evidence of gross structural abnormality.
The proband’s karyotype at a resolution of about
350 bands was normal. NimblegenHuman CGH 3 × 720 K
Whole-Genome Tiling v3.1 Array analysis [13] of her
genomic DNA showed a 241 Kb interstitial homozygous
deletion at 11p14.2 (Figure 2A-B). The complete geno-
type of the proband is therefore arr 11p14.2 (26,954,789-
27,196,089) × 0. We used QPCR as previously described
[14] to confirm this rearrangement in the proband and
to show that both parents are heterozygous for the dele-
tion (Figure 2B-C). This region encompasses Fibin (Fin
Bud Initiation Factor Homolog) and BBOX1 (butyrobe-
taine-gamma 2-oxoglutarate dioxygenase 1) (Figure 2B),
a TGF-beta dependent gene that encodes a secreted
protein essential for pectoral fin bud initiation in zeb-
rafish [15,16] and an essential component of de novo
carnitine biosynthesis [5,10], respectively. A similar al-
most fully overlapping heterozygous 225 kb deletion
(Figure 2B) was suggested to be the cause of Primrose
syndrome (OMIM#259050) at the heterozygote state [17].
The absence of ossified ear cartilage and muscle wasting
specific to this pathology in the proband and both her
parents, who are homo- and heterozygote for this
rearrangement, respectively, goes against the implication
of this deletion in this syndrome. Corroboratingly, some
patients described in DECIPHER inherited similar
deletions from their unaffected parents [18].
Figure 2 Proband’s chromosome 11 genotype (A) NimblegenHuman CGH 3 × 720 K Whole-Genome Tiling array profile of proband’s
chromosomes 11. The homozygously deleted segment is pinpointed by a red arrow (B) Chromosomal position (top, marked by red box) and
extents (bottom, red rectangles) of the homozygote deletion identified in the proband (top) and the heterozygote deletion described in a
patient affected by Primrose syndrome [17] (bottom) in the UCSC genome browser. Both rearrangements encompass the Fibin and BBOX1 genes
(GENCODE genes indicated in blue at the bottom of the panel [19]). The positions of the amplimers used to confirm the array CGH results are
indicated by ticks (153P2-153P4). (C) Relative DNA amount was quantified by QPCR at human chromosome 11 loci defined in panel (B) for the
proband, her mother and father, as well as an unaffected control. Data from three amplification reactions are represented as mean ± S.D.
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in dry blood spot using tandem mass spectrometry (MVZ
wagnerstibbe für Laboratoriumsmedizin). The indices of
common blood metabolites, electrolytes, liver function
tests, creatine phosphokinase, lipid profile, blood gas and
amino acid profiles were all in the normal range in par-
ticular that of acyl-carnitines and isovaleryl carnitine
(Table 2). A detailed analysis of the different acylcarnitine
levels at 42 and 60 months of age showed that all evalu-
ated acylcarnitines were in reference ranges, whereas
free carnitine (FC) (25 and 19 μmol/L) was close to
the normal lower limit (20–70 μmol/L) (Table 3). The
proband’s acylcarnitine (15.5 μmol/L in proband, normal
range 4–28 μmol/L) to free carnitine (AC/FC) ratio was
normal however (age-specific range 0.1-0.8) (Table 3).
Discussion
Carnitine is a critical molecule in the transport of fatty
acids to the mitochondria and their subsequent beta-
oxidation. Its homeostasis is maintained through oral
intake, renal reabsorption and de novo biosynthesis.
Although, the importance of carnitine dietary intake andrenal reabsorption were thoroughly studied [9,20-23], the
impact of de novo biosynthesis remains unclear as we lack
animal models and a single patient deficient in enzymes
involved in the carnitine biosynthesis pathway was de-
scribed [8,11,12].
The female patient described here was referred to our
genetic counseling and cytogenetic service because of
microcephaly, dysmorphic features and IUGR. Array CGH
revealed a homozygous deletion within chromosomal
band 11p14.2 that deletes both the Fibin and the BBOX1
genes, probably resulting in absence of de novo carni-
tine biosynthesis. The evaluation of metabolites involved
directly or indirectly in the fatty acid b-oxidation pathway
showed an increased ratio of AC/FC in the proband at 42
but not at 60 months of age (Table 3). Previous studies
showed that such an increased ratio is an indicator of
carnitine insufficiency; a situation in which there is inad-
equate free carnitine in response to an increase in meta-
bolic needs [24-26]. It was further postulated that the
AC/FC ratio reflects the intramitochondrial acyl-CoA/
CoA ratio and thus that its alteration could be indica-
tive of mitochondrial dysfunction [4]. The clinical and
Table 2 Proband’s metabolic investigations
FBS (P) 98 mg/dL Sodium (P) 140 mEq/L
BUN (P) 11 mg/dL Potassium (P) 3.8 mEq/L
Creatinine (P) 0.6 mg/dL Chloride (P) 102 mEq/L
Cholesterol (P) 164 mg/dL 17-OH-Progesterone (DBS) < 5 nmol/L
Triglyceride (P) 63 mg/dL TSH (DBS) < 4 mU/L
HDL (P) 49 mg/dL Ketone (U) Negative
LDL (P) 102 mg/dL Amino-acid TLC (U) Normal pattern
SGOT (P) 22 IU/L Ferric Chloride Test (U) Negative
SGPT (P) 18 IU/L DNPH Test (U) Negative
CPK (P) 167 IU/L Na-Nitropruside Test (U) Negative
Lactate (P) 7.8 mg/dL Amino-acids (DBS) (TMS) unremarkable
Ammonia (B) 44 mcg/dL Acylcarnitines (DBS) (TMS)* unremarkable*
Galactose (DBS) < 18 mg/dL Isovalerylcarnitine (DBS) unremarkable
GALT (DBS) > 20% act Glutaric acid (DBS) unremarkable
PH (VBG) 7.392 Citrulline (DBS) unremarkable
PCO2 (VBG) 32.1 mmHg Arginosuccinate (DBS) unremarkable
HCO3 (VBG) 19 mmol/L Succinylacetone (DBS) <5 μmol/L
BE (VBG) −3.4 mmol/L Biotinidase (DBS) >40%act
*The detailed acylcarnitines results are further detailed in Table 3.
P: Plasma, B: Blood, U: Urine, FBS: Fasting Blood Sugar, BUN: Blood Urea Nitrogen, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, SGOT: Serum
Glutamic Oxaloacetic Transaminase, SGPT: Serum Glutamic Pyruvic Transaminase, CPK: Creatine Phosphokinase, GALT: Galactose-1-phosphate uridylyltransferase,
VBG: venous Blood Gas, BE: Base Excess, TSH: Thyroid Stimulating Hormone, TLC: Thin Layer Chromatography, DNPH: Dinitrophenyl Hydrazine, DBS: Dry Blood
Spot, TMS: Tandem Mass Spectroscopy.
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with the described carnitine deficiency disorders [27-32]
even if her levels of free carnitine were close to the lower
limit of normal range demonstrating that the hypothesis
that a defect in carnitine biosynthesis will not manifestTable 3 Proband’s carnitine and acylcarnitine profile
Acyl carnitine Quantity1st (μmol/L) Quantity2nd (μmol/L)
C0 (FC) 25.00 19
C2 15.30 6.5
C3 0.73 0.2
C3-DC 0.04 0.04
C4 0.63 0.46
C4-DC 1.10 0.41
C5 0.10 0.07
C5-DC 0.06 0.04
C5-OH 0.17 0.1
C5:1 0.06 0.04
C6 0.26 0.18
C6-DC 0.00 0
C8 0.10 0.07
C10 0.16 0.16
C10:1 0.15 0.09
1st: Measurements were done after 12 hours fasting at 42 months of age.
2nd: Measurements were done after 12 hours fasting at 60 months of age.itself as a systemic carnitine deficiency in omnivorous
humans [8]. Corroboratingly, the TMLHE-deficient pa-
tients showed normal plasma carnitine level [11,12].
It is unclear if the clinical features shown by the pro-
band, such as microcephaly for example, are associatedAcyl carnitine Quantity1st (μmol/L) Quantity2nd (μmol/L)
C12 0.13 0.17
C12:1 0.04 0.12
C14 0.08 0.03
C14:1 0.05 0.03
C14:2 0.02 0.03
C14-OH 0.01 0.02
C16 0.65 0.41
C16:1 0.06 0.03
C16-OH 0.01 0.01
C18 0.42 0.26
C18:1 0.59 0.28
C18:1-OH 0.01 0.01
C18:2 0.16 0.07
C18:2-OH 0.01 0.01
AC/FC 0.84 0.52
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the different observed phenotypes could be associated to
the absence of the Fibin gene, the second gene encom-
passed within the 11p14.2 deletion. Fibin is a secreted
protein identified in zebrafish, mice and humans poten-
tially acting downstream of retinoic acid and wnt signal-
ing. It is essential for pectoral fin bud initiation and tbx5
expression in zebrafish [16]. Alternatively they could be
triggered by the reported perturbation of expression of
copy-normal genes that neighbor structural rearrange-
ment [33-37] or an unidentified recessive mutation inher-
ited from both of her parents. Further studies are required
to discriminate these different possibilities. Of note, con-
sanguineous marriage is common practice and increasing
in frequency in Iran [38,39]. It was suggested, however,
that carnitine biosynthesis may be a risk factor for
nondysmorphic autism as the TMLHE-deficient patient
was identified in an autism spectrum disorder (ASD) co-
hort [11,12]. While our patient showed some dysmorph-
isms and global developmental delay she did not present
autistic traits. Correspondingly she was microcephalic, a
feature generally associated with schizophrenia rather
than ASD that is generally associated with the mirroring
macrocephaly [40-42].Conclusion
In conclusion, we present to our knowledge, the first
patient with homozygous deletion of BBOX1, the second
individual with a complete defect in carnitine de novo
biosynthesis. She presents a mild decrease in free carni-
tine level but no clinical manifestations of carnitine defi-
ciency disorders, suggesting that dietary carnitine intake
and renal reabsorption are sufficient for carnitine homeo-
stasis in omnivorous individuals.Consent
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